Report Scope & Overview:
The Clinical Trial Imaging Market Size was valued at USD 925.01 million in 2022, and is expected to reach USD 1818 million by 2030 and grow at a CAGR of 8.8% over the forecast period 2023-2030.
A clinical trial is an important part of the process of developing a pharmacological treatment. Clinical preliminary imaging advances has supported the decrease of medication preliminary expenses. Clinical imaging is a significant piece of the clinical advancement of new life science drugs. The visual quality extensively affects the compound's general presentation. A wide range of sicknesses can be recognized and analyzed utilizing clinical preliminary imaging. The technology aids in the analysis of human physiology, allowing for the development of disease prevention measures.
To get more information on Clinical Trial Imaging Market - Request Sample Report
R&D budgets should be increased.
The pharmaceutical and biotechnology industries are seeing rapid growth.
CROs are becoming more prevalent.
Imaging systems are expensive to implement.
Countries that are developing
New imaging modalities, molecular probes, contrast agents, and radiopharmaceuticals are all being developed.
Clinical studies are expensive.
IMPACT OF COVID-19
The advancement of the COVID-19 pandemic has adjusted how clinical treatment is conveyed all over the planet. The COVID-19 pandemic has had a substantial impact on the clinical trial imaging business, with unfavorable changes in rules and recommendations, the closure of manufacturing facilities owing to lockdowns inventory network disturbances, and clinical preliminary enrollment gives all having an adverse consequence. Furthermore, due to lockdowns, the supply of clinical trial imaging goods to end customers has been restricted due to constrained operations in most businesses, insufficient funding for research and academic institutes, and difficulty in providing essential/post-sales services. Furthermore, this is a service-intensive sector, and due to constraints imposed to curb the spread of COVID-19, providing services has become challenging.
As a result of the pandemic forcing the temporary closure of various research centers around the world, several current experiments were put on hold.
Despite the difficult circumstances, industries are gradually recovering, and supply and distribution lines have reopened. While the number of studies for diseases like HIV and tuberculosis declined, focus shifted to COVID-19 diagnostics and therapies, increasing the demand for clinical trial imaging.
By Product and Service Type
Services and software make up the clinical trial imaging market. Because of increased R&D spending and growth in the pharmaceutical and biotechnology industries, the services category accounted for the highest proportion of the clinical trial imaging market in 2020.
By Modality Type
Contingent upon the methodology, the clinical trial imaging market is partitioned into figured tomography, attractive reverberation imaging, ultrasound, positron outflow tomography, X-beam, echocardiography, and different modalities. The computed tomography category held the biggest proportion in 2021. This market is driven by factors such as an increase in the number of CROs, an increase in R&D spending, and expansion in the pharmaceutical and biotechnology industries.
By Therapeutic area Type
Oncology, infectious diseases, neurology, CVS, endocrinology, immunological condition, and other therapeutic areas are the therapeutic areas in which the clinical trial imaging market is segmented. The oncology section was the most dominant in 2021. The growth of the pharmaceutical and biotechnology industries, as well as increased R&D spending, are driving this market.
By End User
Pharmaceutical businesses, biotechnology firms, medical device manufacturers, contract research organisations, university and government research institutes, and other end users have been categorised in the clinical trial imaging market. Pharmaceutical businesses had the highest share of the clinical trial imaging market in 2020. The expansion of this market is being fueled by an increase in pharmaceutical and biotechnology businesses, an increase in the number of CROs, and an increase in R&D spending.
KEY MARKET SEGMENTATION:
By Product and Service Type
By Modality Type
Positron Emission Tomography
By Therapeutic area Type
By End User
Medical Device Manufacturer
Contract Research Organizations
Academic and Government Research Institutes
Need any customization research on Clinical Trial Imaging Market - Enquiry Now
North America, Europe, Asia Pacific, and the Rest of the World are the regions that make up the global clinical trial imaging market. During the projection period, the Asia Pacific region is expected to increase the most. The regional market is expanding due to an increase in the incidence of chronic diseases and a growing demand for better diagnostic instruments. Aside from that, the market is expected to increase because to the increasing need for specialised and high-quality healthcare facilities to improve patient lives.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
Some of the major key players of Clinical Trial Imaging Market are as follows: Biomedical Systems Corp, Bio Telemetry, Cardiovascular Imaging Technologies, IXICO plc, Intrinsic Imaging, Med pace, Navetas Life Sciences, Pro scan Imaging, Resonance Health, Radiant Sage LLC and Other Players.
Biomedical Systems Corp-Company Financial Analysis
|Market Size in 2022||US$ 925.01 Million|
|Market Size by 2030||US$ 1818 Million|
|CAGR||CAGR of 8.8% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product and Service Type (Services, Software)
• By Modality Type (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-ray, Echocardiography)
• By Therapeutic area Type (Oncology, Infectious Diseases, Neurology, CVS, Endocrinology, Immunological Disorder)
• By End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturer, Contract Research Organizations, Academic and Government Research Institutes)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Clinical Trial Imaging Market are as follows: Biomedical Systems Corp, Bio Telemetry, Cardiovascular Imaging Technologies, IXICO plc, Intrinsic Imaging, Med pace, Navetas Life Sciences, Pro scan Imaging, Resonance Health, and Radiant Sage LLC.|
|DRIVERS||• R&D budgets should be increased.
• The pharmaceutical and biotechnology industries are seeing rapid growth.
• CROs are becoming more prevalent.
|RESTRAINTS||• Imaging systems are expensive to implement.|
Ans: The Clinical Trial Imaging Market Size was valued at US$ 925.01 Mn in 2022.
Services, Software are the sub segments of Clinical Trial Imaging market.
Key drivers of the Clinical Trial Imaging Market is the pharmaceutical and biotechnology industries are seeing rapid growth, and CROs are becoming more prevalent.
A clinical trial is an important part of the process of developing a pharmacological treatment. Clinical preliminary imaging advances has supported the decrease of medication preliminary expenses. Clinical imaging is a significant piece of the clinical advancement of new life science drugs.
Ans: The Clinical Trial Imaging Market is to grow at a CAGR of 8.8% over the forecast period 2023-2030.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
220.127.116.11 United Kingdom
18.104.22.168 South Korea
22.214.171.124 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Clinical Trial Imaging Market Segmentation, By Product and Service Type
9. Clinical Trial Imaging Market Segmentation, By Modality Type
9.1 Computed Tomography
9.2 Magnetic Resonance Imaging
9.4 Positron Emission Tomography
10. Clinical Trial Imaging Market Segmentation, By Therapeutic Area Type
10.2 Infectious Diseases
10.6 Immunological Disorder
11. Clinical Trial Imaging Market Segmentation, By End User
11.1 Pharmaceutical Companies
11.2 Biotechnology Companies
11.3 Medical Device Manufacturer
11.4 Contract Research Organizations
11.5 Academic and Government Research Institutes
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13. Company Profiles
13.1 Biomedical Systems Corp
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.3 Cardiovascular Imaging Technologies
13.4 IXICO plc
13.5 Intrinsic Imaging
13.6 Med pace
13.7 Navetas Life Sciences
13.8 Pro scan Imaging
13.9 Resonance Health
13.10 Radiant Sage LLC.
14. Competitive Landscape
14.1 Competitive Benchmark
14.2 Market Share Analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
In 2022, The Multiple Myeloma Market size amounted to USD 21748.15 Million & is estimated to reach USD 47646 Million by 2030 and increase at a compound annual growth rate of 10.3% between 2023 and 2030.
The Veterinary Therapeutics Market size was assessed at USD 31.54 billion in 2022 and is supposed to develop at a build yearly development rate (CAGR) of 7.3% from 2023 to 2030, and is expected to reach USD 55.42 billion by 2030.
The Smart Hospitality Market is anticipated to increase at a CAGR of 30.2% from 2023 to 2030, from a value of USD 13.4 billion in 2022 to USD 110.6 billion in 2030.
The Digital Therapeutics (DTx) Market size was estimated at USD 4.8 billion in 2022 and is expected to reach USD 41.63 billion by 2030 at a CAGR of 31% during the forecast period of 2023-2030.
The Echocardiography market was estimated at US$ 1.76 billion in 2022 and is expected to reach US$ 3.05 billion by 2030. and is anticipated to increase at a CAGR of 7.1% predicted for the forecast period of 2022-2030.
The Cone Beam Computer Tomography (CBCT) Market Size was valued at USD 483.83 million in 2022, and is expected to reach USD 1.18 billion by 2030, and grow at a CAGR of 11.9% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone